APA Clinical eFOCUS is a continuation of the FOCUS program of lifelong learning and is approved by ABPN as a self-assessment activity for 2 AMA PRA Category 1 Credits™. Prescribing of atypical antipsychotics has expanded beyond the indications, for which they have been approved, but their effectiveness, benefits, and adverse effects in off-label uses are not well understood. A grant (#5R18HS021944) from the Agency for Healthcare Research and Quality (AHRQ) has funded APA’s development of a free CME program to disseminate the findings of the 2011 AHRQ Reportas well as newer evidence. The goal of the program is to help physicians make informed decisions about treatments based on the evidence for the off-label use of these drugs. This is a multipart interactive CME program consisting of a multimedia series of 10 learning eFOCUS clinical vignettes and a self-assessment test.
- General Member - Free
- Resident-Fellow Member - Free
- Non-Member - Free
ESTIMATED TIME TO COMPLETE: 2 hour
Begin Date: May 1, 2015
End Date: December, 2016 Contact email@example.com for questions about this course Contact firstname.lastname@example.org for technical assistance
Psychiatrists and all other physicians, as well as all clinicians with an interest in evidence based prescribing for psychiatric disorders.
1. Clinicians will review evidence for treatment of psychiatric disorders 2. Clinicians will review the evidence for the risks and benefits associated with atypical antipsychotic use for off label indications; 3. Clinicians will incorporate knowledge about atypical antipsychotic use for off label indications into practice; 4. Clinicians will identify areas where more study is needed
This eFOCUS provides an opportunity to share your opinion and see how others approach the same case. 1. Start by reading the vignette, answering the questions, reviewing the rationale, references, To Learn More, and suggested articles 2. Complete the About Me section and Evaluation Survey 3. Claim and Print your certificate
The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The APA designates this enduring material for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim credit commensurate with the extent of their participation in the activity. This Self-Assessment CME program has been reviewed and is approved for a maximum of 2 AAPA Category 1 Self-Assessment CME credits by the Physician Assistant Review Panel. Approval is valid until December 31, 2016. Physician Assistants should claim only the credit commensurate with the extent of their participation in the activity. This program was planned in accordance with AAPA’s CME Standards. MOC Part 2 Credit - The American Board of Psychiatry and Neurology has reviewed the APA program, Understanding The Evidence For Off Label Use Of Atypical Antipsychotics and has approved this program (each clinical module) for MOC Part 2 – self-assessment.
APA reports MOC completion data on behalf of our members directly to ABPN, however, diplomates are still required to log on to their ABPN Physician Folios at least once per calendar year to attest to completion of their MOC activities.
Robert Boland, M.D., Professor of Psychiatry & Human Behavior, Brown Alpert Medical School; Reports Reports no financial relationships with commercial interests. Ian A. Cook, M.D., Chief Medical Officer and Senior Vice President, NeuroSigma and Professor of Psychiatry, David Geffen School of Medicine and Semel Institute for Neuroscience and Human Behavior at UCLA; Disclosures – past five years: Grant Support: Aspect Medical Systems/Covidien, Cyberonics, Eli Lilly, MedAvante, Merck, Neuronetics, Novartis, Pfizer, Seaside Therapeutics, Sepracor, Shire. Adviser/Consultant: Allergan, Ascent Media, Bristol-Myers Squibb, Cyberonics, Eli Lilly, Forest, Janssen, Neuronetics, NeuroSigma, NIH (ITVA), Pfizer, Scale Venture Partners, VA (DSMB) ; Speaker: Bristol-Myers Squibb, CME LLC, Eli Lilly, Medical Education Speakers Network, Neuronetics, NeuroSigma, Pfizer, Wyeth. Biomedical Device Patents assigned to the University of California. Employee and Stock Options: NeuroSigma. David Fogelson, M.D., Clinical Professor of Psychiatry, UCLA Department of Psychiatry and Bio-behavioral Sciences; Disclosures - Research Support: Genentech. Joel Yager, MD, Professor of Psychiatry, University of Colorado School of Medicine; Reports Reports no financial relationships with commercial interests. Eve Moscicki, SC.D., M.P.H, PRN, Director, Practice Reach Network, APA Division of Research; Reports Reports no financial relationships with commercial interests. Tristan Gorrindo, MD., Director of Education, American Psychiatric Association; Reports Reports no financial relationships with commercial interests. Annelle Primm, M.D., MPH, Former APA Deputy Director; Reports Reports no financial relationships with commercial interests. Deborah J. Hales, M.D., Former Director, APA Division of Education; Reports Reports no financial relationships with commercial interests.
For PC users, we recommend using a computer that is running the most recent version of Microsoft Windows. For Macintosh users, we recommend using a computer that is running OS X or later. Although the presentations and website can be viewed on any browser, we suggest Google Chrome for PC users and the latest version of Firefox for Macintosh users. Make sure your computer's software and browsers are updated regularly for an optimal experience. Due to the media-rich content, we recommend viewing programs at a minimum screen resolution of 800 x 600 pixels, but preferably 1024 x 768 pixels.